Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

被引：28

作者：

Cattrini, Carlo ^{[1
,2
,3
]}

Espana, Rodrigo ^{[4
]}

Mennitto, Alessia ^{[1
,2
]}

Bersanelli, Melissa ^{[5
,6
]}

Castro, Elena ^{[7
,8
]}

Olmos, David ^{[9
,10
]}

Lorente, David ^{[11
]}

Gennari, Alessandra ^{[1
,2
]}

机构：

[1] Maggiore Carita Univ Hosp, Med Oncol, I-28100 Novara, Italy

[2] Univ Eastern Piedmont UPO, Dept Translat Med DIMET, I-28100 Novara, Italy

[3] Univ Genoa, Dept Internal Med & Med Specialties DIMI, I-16132 Genoa, Italy

[4] Univ Malaga, Hosp Reg Malaga, Urol Unit, Malaga 29910, Spain

[5] Univ Hosp Parma, Med Oncol Unit, I-43126 Parma, Italy

[6] Univ Parma, Dept Med & Surg, I-43126 Parma, Italy

[7] Inst Invest Biomed Malaga, Genitourinary Canc Translat Res Grp, Malaga 29010, Spain

[8] Hosp Univ Virgen de la Victoria & Reg Malaga, UGCI, Med Oncol, Malaga 29010, Spain

[9] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid 28029, Spain

[10] Inst Biomed Res Malaga, Genitourinary Canc Translat Res Grp, Malaga 29010, Spain

[11] Hosp Prov Castellon, Med Oncol, Castellon De La Plana 12002, Spain

来源：

CANCERS | 2021年 / 13卷 / 18期

关键词：

metastatic castration-resistant prostate cancer; metastatic hormone-sensitive prostate cancer; metastatic hormone-naive prostate cancer; nonmetastatic castration-resistant prostate cancer; chemotherapy; androgen-receptor signaling inhibitors; LuPSMA; PARP inhibitors; ipatasertib; ANDROGEN DEPRIVATION THERAPY; ACETATE PLUS PREDNISONE; PHASE-II TRIAL; ABIRATERONE ACETATE; PATIENTS PTS; DOUBLE-BLIND; OPEN-LABEL; MOLECULAR DETERMINANTS; RADIUM-223; DICHLORIDE; INCREASED SURVIVAL;

D O I：

10.3390/cancers13184522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introduced for the management of the castration-resistant disease. However, no optimal sequencing is still defined, and few randomized comparisons are currently available to identify the approach that maximizes the long-term benefit for these patients. This comprehensive review aims at resuming the current evidence on this topic to help physicians during the treatment choice for patients with advanced prostate cancer. The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or PTEN).

引用

页数：27

共 162 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2] Genomic correlates of clinical outcome in advanced prostate cancer [J].

Abida, Wassim ;

Cyrta, Joanna ;

Heller, Glenn ;

Prandi, Davide ;

Armenia, Joshua ;

Coleman, Ilsa ;

Cieslik, Marcin ;

Benelli, Matteo ;

Robinson, Dan ;

Van Allen, Eliezer M. ;

Sboner, Andrea ;

Fedrizzi, Tarcisio ;

Mosquera, Juan Miguel ;

Robinson, Brian D. ;

De Sarkar, Navonil ;

Kunju, Lakshmi P. ;

Tomlins, Scott ;

Wu, Yi Mi ;

Rodrigues, Daniel Nava ;

Loda, Massimo ;

Gopalan, Anuradha ;

Reuter, Victor E. ;

Pritchard, Colin C. ;

Mateo, Joaquin ;

Bianchini, Diletta ;

Miranda, Susana ;

Carreira, Suzanne ;

Rescigno, Pasquale ;

Filipenko, Julie ;

Vinson, Jacob ;

Montgomery, Robert B. ;

Beltran, Himisha ;

Heath, Elisabeth I. ;

Scher, Howard I. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen ;

Schultz, Nikolaus ;

deBono, Johann S. ;

Demichelis, Francesca ;

Nelson, Peter S. ;

Rubin, Mark A. ;

Chinnaiyan, Arul M. ;

Sawyers, Charles L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) :11428-11436

[3] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J].

Abida, Wassim ;

Cheng, Michael L. ;

Armenia, Joshua ;

Middha, Sumit ;

Autio, Karen A. ;

Vargas, Hebert Alberto ;

Rathkopf, Dana ;

Morris, Michael J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Carbone, Emily ;

Barnett, Ethan S. ;

Hullings, Melanie ;

Hechtman, Jaclyn F. ;

Zehir, Ahmet ;

Shia, Jinru ;

Jonsson, Philip ;

Stadler, Zsofia K. ;

Srinivasan, Preethi ;

Laudone, Vincent P. ;

Reuter, Victor ;

Wolchok, Jedd D. ;

Socci, Nicholas D. ;

Taylor, Barry S. ;

Berger, Michael F. ;

Kantoff, Philip W. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Solit, David B. ;

Gopalan, Anuradha ;

Scher, Howard I. .

JAMA ONCOLOGY, 2019, 5 (04) :471-478

[4] Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making [J].

Abida, Wassim ;

Armenia, Joshua ;

Gopalan, Anuradha ;

Brennan, Ryan ;

Walsh, Michael ;

Barron, David ;

Danila, Daniel ;

Rathkopf, Dana ;

Morris, Michael ;

Slovin, Susan ;

McLaughlin, Brigit ;

Curtis, Kristen ;

Hyman, David M. ;

Durack, Jeremy C. ;

Solomon, Stephen B. ;

Arcila, Maria E. ;

Zehir, Ahmet ;

Syed, Aijazuddin ;

Gao, Jianjiong ;

Chakravarty, Debyani ;

Vargas, Hebert Alberto ;

Robson, Mark E. ;

Vijai, Joseph ;

Offit, Kenneth ;

Donoghue, Mark T. A. ;

Abeshouse, Adam A. ;

Kundra, Ritika ;

Heins, Zachary J. ;

Penson, Alexander V. ;

Harris, Christopher ;

Taylor, Barry S. ;

Ladanyi, Marc ;

Mandelker, Diana ;

Zhang, Liying ;

Reuter, Victor E. ;

Kantoff, Philip W. ;

Solit, David B. ;

Berger, Michael F. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Scher, Howard I. .

JCO PRECISION ONCOLOGY, 2017, 1 :1-26

[5]

Agarwal N, 2020, J CLIN ONCOL, V38

[6] Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies [J].

Al Nakouzi, Nader ;

Le Moulec, Sylvestre ;

Albiges, Laurence ;

Wang, Chris ;

Beuzeboc, Philippe ;

Gross-Goupil, Marine ;

Rouge, Thibault de la Motte ;

Guillot, Aline ;

Gajda, Dorota ;

Massard, Christophe ;

Gleave, Martin ;

Fizazi, Karim ;

Loriot, Yohann .

EUROPEAN UROLOGY, 2015, 68 (02) :228-235

[7] Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial [J].

Annala, M. ;

Fu, S. ;

Bacon, J. V. W. ;

Sipola, J. ;

Iqbal, N. ;

Ferrario, C. ;

Ong, M. ;

Wadhwa, D. ;

Hotte, S. J. ;

Lo, G. ;

Tran, B. ;

Wood, L. A. ;

Gingerich, J. R. ;

North, S. A. ;

Pezaro, C. J. ;

Ruether, J. D. ;

Sridhar, S. S. ;

Kallio, H. M. L. ;

Khalaf, D. J. ;

Wong, A. ;

Beja, K. ;

Schonlau, E. ;

Taavitsainen, S. ;

Nykter, M. ;

Vandekerkhove, G. ;

Azad, A. A. ;

Wyatt, A. W. ;

Chi, K. N. .

ANNALS OF ONCOLOGY, 2021, 32 (07) :896-905

[8]

Antonarakis ES, 2020, JCO PRECIS ONCOL, V4, P370, DOI [10.1200/PO.19.00399, 10.1200/po.19.00399]

[9] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study [J].

Antonarakis, Emmanuel S. ;

Piulats, Josep M. ;

Gross-Goupil, Marine ;

Goh, Jeffrey ;

Ojamaa, Kristiina ;

Hoimes, Christopher J. ;

Vaishampayan, Ulka ;

Berger, Ranaan ;

Sezer, Ahmet ;

Alanko, Tuomo ;

de Wit, Ronald ;

Li, Chunde ;

Omlin, Aurelius ;

Procopio, Giuseppe ;

Fukasawa, Satoshi ;

Tabata, Ken-ichi ;

Park, Se Hoon ;

Feyerabend, Susan ;

Drake, Charles G. ;

Wu, Haiyan ;

Qiu, Ping ;

Kim, Jeri ;

Poehlein, Christian ;

de Bono, Johann Sebastian .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[10] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

← 1 2 3 4 5 6 7 8 9 10 →